Biomerica Inc Revenue Growth Rates (BMRA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Biomerica Inc   (NASDAQ: BMRA)
 

BMRA's Revenue Growth by Quarter and Year

Biomerica Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BMRA Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter May 0.88
3rd Quarter February 0.99
2nd Quarter November 1.21
1st Quarter August 1.38
FY 4.46

BMRAs Annual Revenue
Biomerica Inc 's Revenue in the fiscal year 2026 $ 4.45 millions
Biomerica Inc 's Revenue in the fiscal year 2025 $ 5.31 millions
Biomerica Inc 's Revenue in the fiscal year 2024 $ 5.42 millions
Biomerica Inc 's Revenue in the fiscal year 2023 $ 5.34 millions
Biomerica Inc 's Revenue in the fiscal year 2022 $ 18.87 millions




BMRA Revenue fourth quarter 2025 Y/Y Growth Comment
Biomerica Inc achieved in the fourth quarter 2025, above Company average Revenue increase of 16.8% year on year, to $ 0.88 millions.

Looking into fourth quarter 2025 results within In Vitro & In Vivo Diagnostic Substances industry 9 other companies have achieved higher Revenue growth. While Biomerica Inc ' s Revenue growth of 16.8% ranks overall at the positon no. 3027 in the fourth quarter 2025.


BMRA Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter May 16.8 % -33.04 % 0.9 % -79.06 %
3rd Quarter February -11.61 % 9.8 % -8.11 % -85.51 %
2nd Quarter November -26.22 % 4.46 % 6.08 % -68.17 %
1st Quarter August -23.76 % 5.85 % 4.27 % 30.16 %
FY   -16.24 % -1.85 % 1.5 % -

Financial Statements
Biomerica Inc 's fourth quarter 2025 Revenue $ 0.88 millions BMRA's Income Statement
Biomerica Inc 's fourth quarter 2024 Revenue $ 0.75 millions Quarterly BMRA's Income Statement


BMRA Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter May -11.52 % -33.04 % 9.8 % 0 %
3rd Quarter February -18.18 % -31.71 % -35.03 % -25 %
2nd Quarter November -12.32 % -9.39 % -8.19 % -9.76 %
1st Quarter August 84 % 61.61 % 54.05 % -69.06 %
FY (Year on Year)   -16.24 % -1.85 % 1.5 % -


Back to BMRA Growth rate Comparisons >> Back to BMRA Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #10
Healthcare Sector #416
Overall #3027

Revenue Y/Y Growth Statistics
High Average Low
163.05 % 7.3 % -71.87 %
(Aug 31 2022)   (Aug 31 2023)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #10
Healthcare Sector #416
Overall #3027
Revenue Y/Y Growth Statistics
High Average Low
163.05 % 7.3 % -71.87 %
(Aug 31 2022)   (Aug 31 2023)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Biomerica Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
268.28 % 8.2 % -70.95 %
(Nov 30 2021)  


BMRA's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2025 Biomerica Inc disclosed drop in Revenue from the third quarter by -11.52% to $ 0.88 millions, from $ 0.99 millions achived in the previous reporting period.

But that's not important problem, as Biomerica Inc 's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Biomerica Inc 's Revenue growth quarter on quarter, overall rank is 2917.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #7
Healthcare Sector #375
Overall #2917
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #7
Healthcare Sector #375
Overall #2917
Revenue Q/Q Growth Statistics
High Average Low
268.28 % 8.2 % -70.95 %
(Nov 30 2021)  


BMRA's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2025 Biomerica Inc disclosed drop in Revenue from the third quarter by -11.52% to $ 0.88 millions, from $ 0.99 millions achived in the previous reporting period.

But that's not important problem, as Biomerica Inc 's Revenue generally seem to plunge in this quarter.

Within In Vitro & In Vivo Diagnostic Substances industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Biomerica Inc 's Revenue growth quarter on quarter, overall rank is 2917.


Biomerica Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(May 31 2026)		 12 Months Ending
(Feb 28 2026)		 12 Months Ending
(Nov 30 2025)		 12 Months Ending
(Aug 31 2025)		 12 Months Ending
(May 31 2025)
Cumulative Revenue 12 Months Ending $ 4.45 $ 4.33 $ 4.46 $ 4.88 $ 5.31
Y / Y Revenue Growth (TTM) -16.16 % -23.84 % -20.08 % -11.35 % -1.92 %
Year on Year Revenue Growth Overall Ranking # 2769 # 40 # 307 # 35 # 1896
Seqeuential Revenue Change (TTM) 2.94 % -2.96 % -8.72 % -8.04 % -6.5 %
Seq. Revenue Growth (TTM) Overall Ranking # 3027 # 55 # 310 # 35 # 2023


Cumulative Revenue growth Comment
Biomerica Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Feb 28 2026. If the fiscal year would end in May 31 2026, Biomerica Inc 's annual Revenue decline would be -16.16% year on year to $4 millions.

In the Healthcare sector 393 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 40 to 2769.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 10
Healthcare Sector # 394
Overall # 2769

Revenue TTM Y/Y Growth Statistics
High Average Low
163.05 %
 7.3 %
-71.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 416
S&P 500 # 3027
Cumulative Revenue growth Comment
Biomerica Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Feb 28 2026. If the fiscal year would end in May 31 2026, Biomerica Inc 's annual Revenue drop would be -16.16% year on year to $4 millions.

In the Healthcare sector 393 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 40 to 2769.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 10
Healthcare Sector # 394
Overall # 2769

Revenue TTM Y/Y Growth Statistics
High Average Low
163.05 %
7.3 %
-71.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 416
S&P 500 # 3027




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BMRA's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending May 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending May 31 2026
Medinotec Inc 24.23%$ 24.230 millions
Biomerica Inc 16.96%$ 16.956 millions


About Biomerica Inc Revenue Growth Rates (BMRA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Biomerica Inc (CIK 73290).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-040851
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Biomerica Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.